READ EMERGERS’ EQUITY RESEARCH ON QLUCORE HERE
QLUCORE: At the vanguard of both oncology research and life science M&A
With a strong trend in oncology and life science R&D in favour of precision medicine, data analysis and AI, Qlucore is uniquely positioned at the forefront with its +200 research customers around the globe. This is also evidenced by the M&A activity we’ve seen internationally in 2023.
With Net Cash of 80 MSEK above the current market cap of 75 MSEK, the low point in valuation (SEK 15 in Sept ’22) should be behind them. We maintain our fair value of 34-46 SEK in 12-24 months, leaving plenty of upside from today’s level, with progress on the CE application process, new license deals, and first Diagnostics sales as the primary triggers.
Johan Widmark | 2023-01-20 08:00
This commissioned research report is for informational purposes only and is to be considered marketing communication. This research report has not been prepared in accordance with legal requirements designed to promote the independence of investment research and Emergers is not subject to any prohibition on dealing ahead of the dissemination of investment research. This research does not constitute investment advice and is not a solicitation to buy shares. For more information, please refer to disclaimer.
DISCLAIMER
